IBA (Ion Beam Applications S.A., EURONEXT), a provider of proton therapy solutions for the treatment of cancer,has announced its business update for the first quarter ending 31 March 2019.
Olivier Legrain, Chief Executive Officer of IBA SA commented: “The start of 2019 has seen an active proton therapy market and strong performance in our Other Accelerators division. We were also pleased to be selected to install a Proteus®Plus system in the important market of China. With an increasing number of proton therapy projects becoming operational in the coming years, IBA’s recurring revenues will continue to grow and will become more predictable.
“We continue to maintain tight cost controls whilst maintaining our unique competitive strengths allowing us to deliver a cutting edge, flexible product offering with the fastest market installation times.”
Proton Therapy Markets & Technology
Proton Therapy Operations
IBA announces business update for first quarter 2019. Appl Rad Oncol.